This is the comparison that actually matters most if you are deciding what to put in your body. It is not really about two similar peptides — it is about two different strategies for the same hormone. Sermorelin is a request: it asks your pituitary to release growth hormone your own body makes. HGH (somatropin) is the delivery: it is recombinant growth hormone itself, manufactured and injected directly, bypassing the pituitary entirely. Those are not two flavors of the same product. They sit in different evidence tiers and, in the United States, in very different legal categories. The gap between the two is larger than most buyers assume going in.
At a glance
| Sermorelin | HGH (somatropin) | |
|---|---|---|
| Mechanism | GHRH analog — stimulates the pituitary to release the body’s own GH; preserves pulsatile release [1] | Recombinant human growth hormone — supplies GH directly, bypassing pituitary regulation |
| FDA status | Not currently approved in any form; discontinued brand, compounded-only today [2] | Multiple currently FDA-approved, actively marketed products (Genotropin, Humatrope, Norditropin, Omnitrope, Serostim, Zomacton, others) [3] |
| What it is approved for | Nothing, currently | Pediatric growth failure (GH deficiency, Prader-Willi syndrome, small-for-gestational-age, Turner syndrome, idiopathic short stature), adult- or childhood-onset GH deficiency, and — for one brand — HIV-associated wasting [3] |
| Direct head-to-head outcome data | Inferior to GH on growth velocity in the one trial that tested both directly [4] | Superior to the GHRH analog on the same trial’s primary outcome [4] |
| Legal status for off-label use (US) | Compounded product; regulatory gray zone but not a felony-specific statute | Federal felony to distribute or possess with intent to distribute for any non-FDA-approved use — up to 5 years, or 10 if involving a minor [5] |
The mechanism, and why it is not just semantics
Sermorelin’s entire pitch rests on a real physiological distinction: because it stimulates your own pituitary rather than flooding your bloodstream with hormone from outside, it should, in theory, preserve your body’s natural pulsatile GH release pattern instead of overriding it. There is genuine trial support for that idea. A year-long pediatric infusion study found that continuous GHRH-analog exposure produced “sustained augmentation of pulsatile GH secretion without evidence of desensitization,” meaning the pituitary kept responding rather than shutting down from constant stimulation [1]. That is the real, evidence-backed argument for a secretagogue over exogenous GH: you are working with your own regulatory system instead of around it. The adult trial literature on sermorelin itself was explicitly framed around avoiding the adverse-effect profile associated with direct recombinant GH replacement in older adults [6]. See the full mechanism explainer for how that request-versus-delivery distinction actually works.
That argument has a real cost, though, and it is the cost that gets left out of most sales pages: a request routed through your own pituitary is only as strong as your pituitary’s remaining capacity to respond. Exogenous GH has no such ceiling. It delivers the hormone directly, regardless of how much, or how little, your own gland can still produce.
The one trial that tested this directly — and it is not close
Most of what is written about sermorelin versus HGH is theoretical, because almost nobody has actually run both in the same trial. One study did. A 1993 randomized controlled trial enrolled 60 children with confirmed growth hormone deficiency and split them into three arms: GHRH analog at a lower dose, GHRH analog at double that dose, or recombinant GH itself. Six months later, the height-velocity results were 9.2 cm/year, 9.3 cm/year, and 14.6 cm/year, respectively (P < 0.01). GH outperformed both GHRH-analog doses on the actual outcome that mattered, growth, and by a wide margin [4]. Doubling the GHRH-analog dose — 30 to 60 µg/kg/day — produced essentially no additional benefit. That tells you the ceiling was not a dosing problem — it was a mechanism problem. See what those trial doses actually were. The same trial found 39 of 40 analog-treated children developed anti-GHRH antibodies. Titers did not correlate with growth outcomes, and the antibodies had mostly cleared nine months after stopping treatment.
This was a trial in genuinely GH-deficient children — arguably the population most likely to respond well to a secretagogue, since their pituitaries, while underperforming, were not entirely non-functional. Even there, actual growth hormone won decisively on the outcome that was measured. That result does not prove sermorelin “does not work” in adults with normal age-related GH decline — a different population, tested in a different trial. But it is the only head-to-head data that exists. And it points the same direction the rest of the sermorelin literature does: real but modest effects from the secretagogue route, versus a stronger, more direct effect from supplying the hormone itself.
The legal gap almost nobody accounts for
This is the part of the comparison buyers consistently underestimate, and it has nothing to do with efficacy. In the United States, distributing — or possessing with intent to distribute — human growth hormone for any use other than an FDA-approved medical purpose is a specific federal felony under 21 U.S.C. § 333(e). It carries up to five years in prison, or up to ten if a minor is involved. The statute defines “human growth hormone” explicitly as somatropin, somatrem, or an analog of either. A conviction is treated as a felony violation of the Controlled Substances Act for forfeiture purposes, with the DEA holding investigative authority [5]. In plain terms: the “anti-aging clinic” model of prescribing actual HGH off-label — for aging, athletic performance, or general wellness rather than a diagnosed deficiency — sits on the wrong side of a specific criminal statute. It is not just an FDA labeling technicality.
Sermorelin’s legal position is different in kind. It is not a scheduled or specially criminalized substance the way HGH distribution is. It occupies the more familiar, if still imperfect, regulatory lane of 503A/503B pharmacy compounding from bulk active ingredient, the same general category as many other compounded medications. That does not make off-label sermorelin use risk-free or fully settled from a regulatory standpoint — sermorelin’s exact placement on FDA’s compounding bulk-substances lists is covered in detail in is sermorelin FDA-approved. But it is a materially different legal exposure than the specific felony statute that attaches to off-label HGH distribution. If you are weighing which of these is riskier to buy from an unclear source, the legal answer and the clinical-evidence answer happen to point the same direction. That is unusual, and worth sitting with.
What this means in practice
If your actual goal is treating a diagnosed growth hormone deficiency, real HGH — an FDA-approved product, prescribed on-label, under a diagnosis that actually qualifies — has decades of approved use. Per the one direct trial available, it also has a stronger effect on the outcome that was measured. Most buyers are not in that group, though. Most are using either compound off-label — for aging, body composition, or general wellness. For them the choice looks different. It is a compounded secretagogue with real but modest evidence and thinner regulatory exposure, against a directly-injected hormone with stronger biological effect but a specific federal felony statute attached to exactly that kind of off-label distribution. That is not a comparison of two similar wellness products. It is a comparison of a request and a delivery, sitting in two very different evidence tiers and two very different legal categories. For sermorelin sellers specifically, the injections board has the pricing.